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Abstract
Background/Aim:Hepatic injury is a hallmark adverse reaction to Valproate (VPA),
a common used drug in the management of numerous CNS disorders, including
epilepsy. DHAhas a myriad of health benefits, including renal- and hepato-protective
effects. Unfortunately, however, the underpinnings of such liver-pertinent VPA- and
DHA-actions remain largely undefined. Accordingly, this study attempted to unveil
the cellular and molecular triggers whereby VPA evokes, while DHA abates,
hepatotoxicity.
Methods:We evaluated activity and/or expression of cellular markers of oxidative
stress, inflammation, and apoptosis in rat liver, following treatment with VPA (500
mg/kg/day) with and without concurrent treatment with DHA (250 mg/kg/day) for
two weeks.
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Results and conclusion: VPA promoted hepatic oxidative stress as evidenced by
enhancing activity/expression of NADPH-oxidase and its subunits, a ROS-
generator, and by accumulation of lipid-peroxides. Moreover, VPA enhanced
hepatic phosphorylation/activation of mitogen-activated protein kinase (MAPK),
and expression of cyclooxygenase-2(COX-2), as proinflammatory signals.
Besides, VPA promoted hepatocellular apoptosis, as attested by enhanced
expression of cleaved caspase-9 and increased number of TUNEL-positive
hepatocytes. Lastly, VPA upregulated levels of hypoxia-inducible factor-1-alpha
(HIF-1α), a multifaceted modulator of hepatocytic biology, and activity of its
downstream antioxidant enzyme heme-oxygenase-1(HO-1). These changes were
significantly blunted by co-administration of DHA. Our findings demonstrate that
VPA activated NADPH-oxidase and HIF-1α to induce oxidative-stress and
hypoxia as initiators of hepatic injury. These changes were further aggravated by
up-regulation of inflammatory (MAPK and COX-2) and apoptotic cascades, but
could be partly lessened by HO-1 activation. Concurrent administration of DHA
mitigated all VPA-induced anomalies.
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1. Introduction
Liver injury is a major public health problem all over the world and it affects
approximately 30% of the US population (Rinella, 2015). More than 900 drugs
have been implicated in inducing liver injury as an adverse effect, a predominantly
compelling reason for drug withdrawal from the market (Friedman et al., 2003).
Valproate (VPA) is a widely used drug for treatment of epileptic seizures, bipolar
and schizoaffective disorders, trigeminal neuralgia, social phobias, migraine pain
and neuropathic pain (Johannessen and Johannessen, 2003). However, VPA has
major adverse reactions, including gastrointestinal disorders (Jahromi et al., 2011),
hemorrhagic pancreatitis, bone-marrow suppression and a more frequently hepatic
injury (Gerstner et al., 2008). Hyperammonemia has been reported in patients
using VPA therapy (Tseng et al., 2014). With chronic use of VPA, 44% of patients
showed elevated serum liver enzymes and lipid peroxidation. Moreover, VPA
therapy is associated with the development of fatty liver (Zimmerman and Ishak,
1982) that can progress to hepatic necrosis, apoptosis. While most of these
reactions are VPA-dose- and time-dependent, some serious ones are not so, as they
involve type-2 unpredictable (idiosyncratic) fatal reactions (Roma-Giannikou
et al., 1999).
VPA is extensively metabolized in the liver via glucuronic acid conjugation,
mitochondrial β-oxidation and cytosolicω-oxidation to producemultiplemetabolites;
some of them are biologically active and could mediate VPA-induced hepatotoxicity.
For instance, 4-ene-valproic (4-ene-VPA) is a more potent hepatotoxic than VPA and
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can trigger oxidative cascades that deplete reduced-glutathione, an indispensable
antioxidant cellular protector (Ji et al., 2010). Moreover, valproate-induced activation
of CYP2E1 and subsequently oxidative stress may provoke serious proteolytic
reactions in hepatocytes, thereby damaging liver cell membranes and leaking out
intracellular enzymes (Ji et al., 2010).
Docosahexaenoic acid/DHA is a biologically active polyunsaturated omega-3 fatty
acid (ω-3 FA). DHA is found mainly in fish oil and the metabolic products of a third
plant-derived ω-3 FA, alpha-linolenic acid (Li and Hu, 2009). DHA has numerous
health benefits as it regulates membrane bound enzymes (Na+/K+-dependent
ATPase) and plays a role in signal transduction by modulating inositol phosphates,
diacylglycerol (DAG), and protein kinase C pathways (Abedi and Sahari, 2014).
Moreover, DHA directly influences biosynthesis, signaling and uptake of serotonin, a
CNS crucial neurotransmitter (Patrick and Ames, 2015). DHA also affects cell
membrane structure and function (Wood et al., 2015) and plays an important role in
controlling malignant, inflammatory, proliferative and vascular diseases (Simopou-
los, 2003). Interestingly, this n-3FA is an approved OTC supplement/drug for both
children and adults, thereby displaying a wide safety margin and high therapeutic
index (El-Mowafy et al., 2011; Patrick and Ames, 2015).
We have previously demonstrated the efficacy of DHA, or its analog (EPA) against
VPA-induced hepatotoxicity, and doxorubicin-evoked renal injury (El-Mesery
et al., 2009; El-Mowafy et al., 2011). Therefore, the current study was undertaken
to extend our previous findings by investigating the molecular basis and
mechanistic pathways whereby VPA evokes, while DHA may abate, hepatotoxici-
ty. The impact and contribution of novel cellular components in VPA-induced
hepatotoxicity that could exacerbate oxidative stress, hypoxia, inflammation and
apoptosis were evaluated, then further challenged by co-administration of DHA.
2. Materials and methods
2.1. Drugs and chemicals
Sodium valproate was obtained from Cayman Chemical Company, USA, and was
dissolved in distilled water. DHA was purchased from Swanson Health Product,
North Dakota, USA, as capsules; each provides 250 mg of pure DHA. DHA was
diluted in corn oil, with equivalent amounts of oil given to all animals in the
control group.
2.2. Animal studies
All procedures with animals were performed in accordance with the Public Health
Service Guide for the Care and Use of Laboratory Animals and Augusta University
guidelines, and approved by the Institutional Animal Care and Use Committee of
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Augusta University. Twelve week old male Sprague Dawley rats were purchased
from Harlan Laboratory and used in the current study. Three group of rats were used
in our study (n = 6–8 rats/group) as follows;Control-group received vehicle (corn oil
daily) for 2 weeks, VPA-group received VPA alone (500 mg/kg PO, daily) for two
weeks, VPA + DHA-group received VPA (500 mg/kg PO, daily), followed by DHA
(250 mg/kg PO, daily) for two weeks. After two weeks of treatment, rats were
terminated using sodium pentobarbital (50 mg/kg, IP) for liver collection. Liver was
isolated, weighed, aliquoted in few tubes and snap frozen in liquid nitrogen. A 10%
(w/v) liver homogenate was prepared in phosphate-buffered saline (PBS) (pH 7.4) for
the assay of hepatic TBARs, NADPH-oxidase, and HO-1. Other frozen liver samples
were homogenized in RIPA buffer for Western blotting (n = 4/group).
2.3. Biochemical determinations
Hepatic thiobarbituric reactive species (TBARs) were assessed spectrophotometri-
cally according to manufacturer instructions (Cayman Chemical, Ann Arbor, MI)
as a marker of oxidative stress. NADPH-oxidase activity was measured by
lucigenin chemiluminescence (5 μmol/L) in the presence of 100 μmol/L NADPH
as previously described (Pye et al., 2014). Briefly, the liver was homogenized in
ice-cold buffer in the presence of protease inhibitors (Phenylmethylsulphonyl-
fluoride 1 mM, Benzamidine-HCl 1 mM, Leupeptin, 0.5 μg/ml, Aprotinin 0.5 μg/
ml, Pepstatin 1 mg/ml, NaF 50 mM). 50 μL of homogenate or buffer control was
added to the wells of a 96-well micro-plate (OptiPlate-96, Perkin-Elmer, Waltham,
MA) and incubated at 37 °C for 30 minutes in the presence of lucigenin (5 μmol/L)
and NADPH, and total count per minute (cpm) was normalized to mg protein.
Hepatic HO-1 activity, a marker of antioxidant pathway, was measured in liver
samples using a commercially available ELISA according to manufacturer's
instructions (Enzo Life Sciences Inc., Farmingdale, NY).
2.4. Homogenization of the liver for protein expression using
Western blotting
Liver samples were homogenized in RIPA buffer in the presence of protease
inhibitors. Protein concentrations were determined by standard Bradford assay
(Bio-Rad, Hercules, CA) using bovine serum albumin as the standard and liver
homogenates were used to determine protein expression levels of hepatic P67,
gp91 phox, HIF-1α, P-MAPK, COX-2, and cleaved caspase-9 using Western
blotting. Thirty-fifty micrograms of liver samples was separated by SDS-PAGE
then transferred onto PVDF membrane. Membranes were blocked in 5% milk in
TBS and were incubated with primary antibodies overnight. The blots were then
washed in TBS-0.1% Tween and incubated with the secondary antibody goat
anti-rabbit or goat anti-mouse (1:5000) conjugated to horseradish peroxidase for 1
hour. Detection was accomplished using enhanced chemiluminescence. Band
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intensity was measured densitometrically and the values were normalized to
β-actin (Sigma, St Louis, MO) using NIH Image J software.
2.5. TUNEL assay
Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling
(TUNEL) assay was used for in situ detection of apoptotic cells with a
commercially available TUNEL kit (Promega, Madison, USA). Propidium iodide
(PI) 1 μg/ml was added as a nuclear counter stain. The number of TUNEL-positive
hepatic cells was counted and average TUNEL positive cells per cross sectional
area were recorded.
2.6. Statistical analyses
All data are presented as mean ± SEM and analyzed using one-way ANOVA
followed by Tukey's post hoc test for multiple group comparisons. Analyses were
performed using GraphPad Prism Version 4.0 software (GraphPad Software Inc.,
La Jolla, CA). For all comparisons, P < 0.05 was considered statistically
significant.
3. Results
We have previously shown protective effects for DHA against VPA-induced
hepatotoxicity. However, the molecular basis of such effects remains unclear.
Accordingly, the current study was designed to assess the roles of oxidative stress,
inflammation and apoptosis in VPA-evoked liver toxicity and their possible
alleviation by DHA.
Because oxidative stress plays a role in the pathogenesis of liver injury, we first
assessed whether VPA could elevate oxidative stress in the rat liver. Accordingly, we
measured hepatic TBARs levels as a marker of lipid peroxidation. Fig. 1A and
Table 1 show that hepatic TBARs levels were significantly elevated in VPA-treated
animals and concurrent administration of DHA abated such VPA-evoked lipid
peroxidation (P < 0.05). Besides, the increase in lipid peroxidation was associated
with activation of NADPH oxidase, the main source of reactive-oxygen species in the
vasculature, in VPA treated rats (Fig. 1B and Table 1). Moreover, VPA up-regulated
expressional levels of the membrane-bound NADPH oxidase catalytic subunit GP91
phox (NOX2) as well as cytoplasmic P67 subunit versus control (Fig. 1C,D).
Combined administration of DHA reduced VPA-induced NADPH oxidase activation
and up-regulation of its subunits. To further gain acumens into the hepatic nuclear
changes occurring in VPA-treated rats due to the elevation in oxidative stress, we
assessed protein expression levels of HIF-1α and subsequent activation of
downstream HO-1 enzyme in the liver (Fig. 2 and Table 1). We also detected a
concurrent upregulation of Nrf-2, an upstream factor from HO-1 (data not shown).
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The elevation in oxidative stress in the livers of VPA-treated rats was associated with
upregulation of HIF-1α, an important modulator of transcription in cellular response
to variations in systemic oxygen, which displays a multifaceted modulating potential
in the mammalian liver (Fig. 2A and Table 1). Likewise, overexpression of HIF-1α
was accompanied by an increase in the hepatic redox-sensitive antioxidant HO-1
level (Fig. 2B and Table 1). Interestingly, DHA treatment reduced the elevation in
expression of hepatic HIF-1α and HO-1 level in VPA-treated rats (Fig. 2).
Inflammation plays a crucial role in the pathogenesis of hepatic injury. Thus, we
presently assessed the impact of VPA on phosphorylation/activation of MAPK and
[(Fig._1)TD$FIG]
Fig. 1. Hepatic TBARs levels (A. NADPH oxidase activity (B), and P67 and gp91 (NOX2) expression
levels relative to β-actin (C&D) in control and valproate (VPA)-treated rats (500 mg/kg PO, daily) with
or without DHA (VPA. 500 mg/kg PO, daily) for two weeks. VPA increased hepatic TBARs levels,
activated NADPH oxidase and up-regulated expression levels of NADPH oxidase subunits P67 and
gp91 phox when compared to control. Co-administration of DHA prevented VPA-induced oxidative
stress. (*P < 0.05 vs. control. #P < 0.05 vs. VPA-treated rats, n = 6–8/group for TBARs and NADPH
oxidase and n = 4 for Western blotting data). Please see Figs. 1S–4S in the Supplementary Material for
full blot images 2016.
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subsequent downstream inflammatory enzymes, such as COX-2 in rat liver. As
shown in Fig. 3, VPA increased hepatic phosphorylation of MAPK (Fig. 3A) and
induced the expression of its downstream inflammatory enzyme COX-2 (Fig. 3B
and Table 1) and these changes were reduced following concurrent administration
of DHA.
Furthermore, to determine whether apoptosis is involved in VPA-induced
hepatotoxicity, we assessed the DNA-fragmentation, a terminal response in
(apoptotic cells) in rat liver using TUNEL assay, and further determined the
Table 1. Detailed raw data for biochemical assessment of NADPH oxidase,
TBARs and HO-1 levels as well as Western blotting densitometric analysis for
HIF-1α and COX-2 in control, VPA and VPA plus DHA treated rats.
Control VPA VPA + DHA
Hepatic TBARs
(nmol/mg protein)
0.8 ± 0.02 1.1 ± 0.06 * 0.9 ± 0.08
Hepatic NADPH oxidase
(OD/mg protein)
26.0 ±0.80 33.0 ± 0.60 * 27.0 ± 1.20 #
Hepatic HIF-1α 1.4 ± 0.07 2.0 ± 0.04 * 1.5 ± 0.08 #
Hepatic HO-1 (ng/mg protein) 0.98 ± 0.07 1.2 ± 0.05 * 0.9 ± 0.05 #
Hepatic COX-2 (DU) 0.7 ± 0.06 1.0 ± 0.07 * 0.74 ± 0.06
Data are expressed as means ± SE of the mean. (*P < 0.05 vs. control and #P < 0.05 vs. VPA-treated
rats, n = 4/group for Western blotting and n = 6 for hepatic TBARs and NADPH-oxidase).
[(Fig._2)TD$FIG]
Fig. 2. Hepatic HIF-1α expression relative to β-actin (A), hemeoxygenase-1 (HO-1) levels (B) in
control and VPA-treated rats with or without DHA daily treatment for two weeks. HIF-1α levels and
HO-1 activity were enhanced in VPA-treated versus control rats, in a DHA-sensitive manner (*P < 0.05
vs. control and #P < 0.05 vs. VPA-treated rats, n = 6–8/group for HO-1 and n = 4/group for HIF-1α
Western blotting). Please see Figs. 5S–6S in the Supplementary Material for full blot images.
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expressional levels of the pro-apoptotic cleaved caspase-9, in the presence and
absence of DHA. VPA caused a significant increase in TUNEL positive cells
(Fig. 4A), while also increased cleaved caspase-9 expression levels. Both
responses to VPA were significantly reduced with DHA administration (Fig. 4B).
It is noteworthy to mention that we also treated a rat group with DHA alone;
however, all results with DHA group were not different from those of control
group, thus these data were not presented.
4. Discussion
We previously demonstrated that DHA can ameliorate VPA-induced hepatotoxici-
ty; however, the underlying molecular mechanisms remain to be delineated. This
study targeted the role of key molecular regulators of VPA-induced hepatotoxicity,
and further sought the capacity of DHA to counterbalance such signals. Our
findings demonstrate that VPA up-regulates NADPH oxidase, ERK1/2 and HIF-
1α, as upstream triggers of oxidative stress, hypoxia, inflammation and apoptosis,
thereby concluding its profound liver injury. Besides, DHA counteracted VPA-
induced hepatotoxicity, by showing anti-oxidant, anti-inflammatory and anti-
apoptotic effects. The anti-oxidant/protective profiles of DHA have been
demonstrated in human neutrophils and retina (Liu et al., 2014).
Valproic acid (VPA) is widely prescribed for children with newly diagnosed
epilepsy; however, it can induce marked hepatotoxicity which could progress to
fatal idiosyncratic reactions (Farinelli et al., 2015). VPA-mediated hepatotoxicity
[(Fig._3)TD$FIG]
Fig. 3. Hepatic P-MAPK relative to MAPK (A) and hepatic COX-2 expression levels relative to β-actin
(B) in livers of VPA-treated rats +/− DHA. DHA treatment diminished the VPA-induced inflammation
(*P < 0.05 vs. control and #P < 0.05 vs. VPA-treated rats, n = 4/group). Please see Figs. 7S–10S in the
Supplementary Material for full blot images.
Article No~e00130
8 http://dx.doi.org/10.1016/j.heliyon.2016.e00130
2405-8440/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
is characterized by steatosis, necrosis, depletion of endogenous antioxidants, and
disruption of mitochondrial membranes (Spiller et al., 2000).
HIF-1α is a transcription factor that plays a crucial role in cellular response to
alterations in systemic oxygen levels in mammals. Accordingly, HIF-1α regulates
transactivation of over 60 genes, such as VEGF and erythropoietin, which assist in
promoting oxygen delivery to hypoxic regions. VPAmodulates HIF-1α expression in
diverse tissues, yet in an equivocal directions. In all cases, however, these effects were
entailed to the known activity of VPA as a Histone deacetylase (HDAC) inhibitor
(Mottamal et al., 2015). Thus, HIF-1α repression by VPA was established in human
renal cancer cells and in rat gut mucosa. Conversely, in a rat brain stroke model, VPA
up-regulated HIF-1α and its downstream proangiogenic factor, vascular endothelial
growth factor (VEGF), (HO-1), thereby enhancing angiogenesis and functional
recovery from ischemia (Wang et al., 2012). In the liver, HIF-1α status has never been
verified in response toVPA treatment. Currently, we showed up-regulation ofHIF-1α
following VPA treatment. In the liver, HIF-1α is reportedly induced to aide steatosis,
apoptosis and inflammatory/necrotic reactions in response to drug-induced toxicity or
environmental insults (Cursio et al., 2008; van Swelm et al., 2012; Zhu et al., 2005).
Sagaciously, because VPA presently evoked similar hepatic insults, while also
induced HIF-1α, similar causalities and implications are warranted. Interestingly,
[(Fig._4)TD$FIG]
Fig. 4. Representative images (200X) of liver sections for TUNEL assay for detection of apoptotic cells
in the presence of Propidium Iodide (PI) as a nuclear counter stain (A), and hepatic cleaved caspase-9
relative to β-actin as a marker of apoptosis (B) in the liver of control and VPA-treated rats with or
without DHA supplementation. DHA significantly reduced number of apoptotic cells and attenuated the
elevation in cleaved caspase-9 expression shown with VPA-treated rats (*P < 0.05 vs. control, n = 4/
group). Please see Figs. 11S–12S in the Supplementary Material for full blot images.
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however, we also found that HO-1, a downstream antioxidant signal to HIF-1α, was
jointly activated, presumably to oppose/counterbalance oxidative stress. Thus,
together, these observations imply that HIF-1α currently stands as a multifaceted
modulator of liver cell integrity and viability in response to VPA treatment. With the
recent mounting interest in defining therapeutic utility to HIF-1α for an array of liver
anomalies (Wilson et al., 2014), further specific/detailed investigations are required
to delineate the exact scenario whereby HIF-1αmodulates VPA-induced liver injury.
We reported that VPA upregulated inflammatory mediators such as COX-2 in the
current study. Furthermore, VPA augmented the abundance of hepatic TUNEL
positive cell and cleaved caspase-9 expression, indicating induction of apoptosis
via hepatic mitochondrial dysfunction. In gastric cancer cell line, the VPA-induced
apoptosis was ascribed to acetylation of histone and tubulin (Yagi et al., 2010).
The MAPK (ERK) pathway can play a role in cell growth and survival, or
alternatively stimulates inflammatory cascades. In the CNS, the ERK pathway is
recruited by neurotrophic factors to maintain neuronal growth, differentiation and
survival in the hippocampus and frontal cortex. This pathway, when disrupted, can
be restored by drugs intended in mood stabilization, depressive mania and bipolar
disorders, like valproate (Einat et al., 2003; Engel et al., 2009). In support, chronic
treatment of rats with valproate promoted levels of MAPK in relevant neurons
(Hao et al., 2004). Likewise, MAPK ablation disrupted animal behavior and
evoked excitements similar to those by psychostimulants such as amphetamine.
These responses to ERK ablation were reversed by VPA and olanzapine, thereby
substantiating the role of ERK signaling as a target in inducing behavioral
anomalies, and for their alleviation by anti-manic drugs (Engel et al., 2009).
Notably as well, HDAC inhibitors were ineffective on such VPA neuronal
responses, implying that VPA can undertake multifaceted triggers to activate the
neuronal ERK cascade (Hao et al., 2004). In contrast to the CNS, a paucity of
information has been available to link VPA with ERK-activity in the liver. Thus,
by far, only one in vitro study reported that VPA activates ERK phosphorylation in
primary human hepatocytes, a response that was mimicked by HDAC inhibitor,
trichostatin-A (Bitman et al., 2014), implying that HDAC inhibition is a primary
stimulus for ERK in human hepatocytes. However, this this study has not looked at
role of oxidative stress or VPA metabolites, possibly due to limited biologic
windows within a cell culture setup.
Currently, in the liver, and following a 2 week of VPA treatment, ERK is up-
regulated, yet appears to play a pathogenic role culminating into liver injury. We
show here for the first time that VPA up-regulates NADPH oxidase (NOX), as a
prime generator of ROS and contributor to oxidative stress. Notably, NOX, in the
liver, has been shown as a crucial mediator of diverse deleterious reactions,
including inflammation, mitogenesis, fibrosis, apoptosis and steatosis (Li et al.,
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2013; Moon et al., 2010). In such latter redox-sensitive anomalies, both ERK and
NOX appear inevitably involved so as to shape responses to toxins, infections, or
malignancies (Chen et al., 2007). Not surprisingly, cross talk activation between
NADPH-oxidase (ROS) and ERK signaling was evident to further recruit
additional factors including HIF-1α, as typically shown in mammary cancer cells
(Moon et al., 2010). Our current results indicate a similar hepatic scenario among
the three latter effectors, and further implicate COX-2 as an inflammatory co-
player, in response to VPA treatment. Congruent to our latest liver finding with
VPA, the association between ERK and COX-2 was revealed with other stimuli
like phorbol-esters and cytokines in mammary cancer cells and murine auditory
cells (Hong and Jang, 2014; Jeong et al., 2007).
VPA is a risk factor for developing serious liver injury in patients with Alpers-
Huttenlocher syndrome (AHS), a neuro-metabolic disorder that can develop into
fatal hepatotoxicity in stressful conditions. Thus, with VPA, this erupts due to
disruption of liver cells, which involves a caspase-9-mediated apoptosis (Li et al.,
2015). It is noteworthy that we have earlier demonstrated, via histopathologic
analyses, that apoptosis occurs in the rat liver after similar VPA treatments (Abdel-
Dayem et al., 2014). Therefore, our present study, sought the impact of VPA on
expression of cleaved caspase-9 in normal liver in absence of other stressful risk
factors, and further attempted to confirm this by an end-point checker for DNA
fragmentation, using the TUNEL assay. Thus, VPA markedly augmented cleaved
caspase-9 levels to induce apoptosis, as confirmed by the risen abundance of
TUNEL-positive hepatocytes. This has been shown to VPA in other non-hepatic
tissues, especially cancer cells, and in neural tissues in neonate-animals (Yochum
et al., 2008). The present apoptotic reactions were sensitive to DHA treatment,
which is consistent with previous observations that DHA supplementation reduces
apoptosis in livers from high fat-fed animals (Schmocker et al., 2007) and necrosis
in response to the cytokine TNF-α (Pacheco et al., 2014).
Caspase-9 has repeatedly been shown as a downstream apoptotic trigger from
upstream stimuli like NOX/ROS, ERK1/2 or COX-2 (Zhang et al., 2003). These
notions prompted us to check for the status of caspase-9, especially where the
activation of the aforementioned effectors has presently occurred with VPA
treatment. Thus, caspase-9 upregulation was evident with VPA, and further
reinforced with TUNEL-assay of hepatocytes. Accordingly, multiple cellular
pathways and molecular effectors accumulate, likely in an inter-dependent fashion,
to orchestrate hepatic injury in response to VPA. With no rival in seen, hepatic
oxidative stress stands as a likely initiator and coordinator of such events. Not
surprisingly, strong antioxidants or their combinations have demonstrated
considerable efficacy against VPA-evoked liver injury (Baran et al., 2006; Chang
and Abbott, 2006). Currently, DHA was a superb antioxidant in the rat liver.
However, beyond that, omega-3 fatty-acids displayed an array of favorable
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molecular responses including suppression of prostaglandin formation, and
activation of peroxisome proliferator-activated receptors (PPARs), members of
the nuclear hormone receptor superfamily of ligand-dependent transcription
factors, which suppress cytokine-mediated inflammation. This was documented
in cell culture setups by using inhibitors of PPAR-gamma, which abolished the
anti-inflammatory response to DHA and EPA fatty acids (Li et al., 2005). DHA
provides anti-inflammatory effect by favoring the formation of anti-inflammatory
prostaglandin E3, at the expense of inflammatory prostaglandin E2. Prostaglandin
E3 also inhibits the synthesis of TNF-α and IL-1β (Maroon et al., 2010).
Furthermore, Chen and colleagues also showed that DHA down-regulated MAPK,
thereby alleviating rodent cholestatic liver injury (Menendez et al., 2004), a
consistent observation with our current results which, altogether, substantiate an
inflammatory role for ERK in liver cells in response to insults of diverse origin.
5. Conclusion
VPA stimulation of molecular triggers of oxidative stress and inflammation such as
NADPH oxidase, ERK and HIF-1α exacerbates hepatic injury. The generated
oxidative stress, hypoxia and inflammation orchestrate further up-regulation of
COX-2 and caspase-9, thereby accentuating hepatocellular apoptosis. HIF-1α
apparently assumes a dual role in response to VPA that is not only deleterious.
Thus, HIF-1α stimulation of HO-1 as a downstream antioxidant enzyme is only
seemingly to lessen the severity of oxidative stress, as implied by the overall
cellular outcomes. DHA appreciably abated all of the VPA-evoked liver injury and
blunted its evoked hepatocellular apoptosis as well. The fact that DHA possesses
anticonvulsant effects (El-Mowafy et al., 2011), and is also able to mitigate liver
adverse reactions to VPA, could suggest a powerful drug-combination regimen in
the future management of epilepsy.
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